Citations

Showing 10 of 108152 citations.

Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience
Wee, Christopher Eing , Costello, Brian A. , Orme, Jacob J. , Quevedo, J. Fernando , Pagliaro, Lance C. , Wee, Christopher

Mayo Clinic

The Prostate | July 13, 2021 | Volume: 81 | Issue: 13 | Pages: 938-943

10.1002/pros.24189 | PMID 34254332 Get It

AbstractIntroductionChemotherapy in combination with immunotherapy has a proven survival benefit compared to chemotherapy alone in extensive stage small cell lung cancer (SCLC) and is the new standard of care. Since extrapulmonary small cell carcinomas (SCCs) are less common, treatment paradigms are reasonably extrapolated from SCLC regimens. We examined our institution's experience utilizing the combination of chemotherapy and immunotherapy (as used in SCLC) for SCC and neuroendocrine carcinoma of the prostate.MethodsUtilizing an institutional database search tool, we queried the electronic medical record to identify patients with SCC or neuroendocrine carcinoma of the prostate who had been treated with atezolizumab and chemotherapy. We recorded patient characteristics, including age, pathology, and disease extent. Treatment characteristics included number of prior treatments, use of concominant androgen deprivation, number of cycles of immunotherapy, and prior systemic therapies (including those for adenocarcinoma of the prostate). Progression free survival (PFS) and overall survival (OS) were the primary outcomes.ResultsWe identified seven men who received atezolizumab for metastatic prostate cancer with a small cell or neuroendocrine component. In six of the seven patients, the combination of carboplatin, etoposide, and atezolizumab was the first‐line of treatment after diagnosis of small cell or neuroendocrine carcinoma. Two of the seven patients had de novo small cell/neuroendocrine pathology, while the other five had transformation from a preexisting adenocarcinoma. In the patients who received chemotherapy plus immunotherapy in the first‐line setting, at a median follow‐up of 6.5 months (range: 1.5–15.1) the median PFS was 3.4 months and median OS was 8.4 months.ConclusionSmall cell or neuroendocrine carcinoma of the prostate was associated with poor survival outcomes despite adding immunotherapy (atezolizumab) to chemotherapy (carboplatin and etoposide). To our knowledge, there has been no demonstrable benefit of adding immunotherapy to chemotherapy in this setting.
Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐versus‐host disease — a real‐world outcomes analysis
Abedin, Sameem , Rashid, Nahid , Nauffal, Mary , Kharfan‐Dabaja, Mohamed A. , Palmer, Jeanne , Larson, Samantha, Holtan, Shernan G. , DeFilipp, Zachariah , Dholaria, Bhagirathbhai , Pidala, Joseph, Khimani, Farhad , Butler, Candace, Alhaj Moustafa, Muhamad, Kharfan-Dabaja, Mohamed A , Hogan, William, Hamadani, Mehdi , Dholaria, Bhagirathbhai R , Holtan, Shernan , Abedin, Sameem , Schroeder, Mark A. , Romee, Rizwan , Moustafa, Muhamad Alhaj , Hogan, William J. , Hefazi, Mehrdad , Jayani, Reena , Grunwald, Michael R. , Hamadani, Mehdi

Mayo Clinic

British Journal of Haematology | July 13, 2021 | Volume: 195 | Issue: 3 | Pages: 429-432

10.1111/bjh.17700 | PMID 34254289 Get It

SummaryRuxolitinib for steroid‐refractory acute graft‐versus‐host disease (SR‐aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib‐resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR‐aGVHD studies.
COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?
Lundström, Kenneth , Barh, Debmalya , Uhal, Bruce D. , Takayama, Kazuo , Aljabali, Alaa A. A. , El‐Aziz, Tarek Mohamed Abd , Lal, Amos , Redwan, Elrashdy M. , Adadi, Parise , Chauhan, Gaurav , Azad, Gajendra Kumar , Rezaei, Nima , Serrano‐Aroca, Ángel , Hassan, Sk. Sarif , Panda, Pritam Kumar , Choudhury, Pabitra Pal , Pizzol, Damiano , Kandimalla, Ramesh , Baetas‐da‐Cruz, Wagner , Mishra, Yogendra Kumar , Palù, Giorgio , Brufsky, Adam , Tambuwala, Murtaza M. , Uversky, Vladimir N. , El-Aziz, Tarek M A , Azad, Gajendra Kumar , Rezaei, Nima , Serrano-Aroca, Ángel , Hassan, Sk Sarif , Panda, Pritam Kumar , Pizzol, Damiano , Kandimalla, Ramesh , Mishra, Yogendra Kumar , Brufsky, Adam M , Tambuwala, Murtaza , Uversky, Vladimir N , Adadi, Parise , Lal, Amos , Baetas-da-Cruz, Wagner , Aljabali, Alaa A A , Chauhan, Gaurav , Redwan, Elrashdy M , Barh, Debmalya , Takayama, Kazuo , Sherchan, Samendra , Bazán, Nicolás G.

Mayo Clinic

Biomolecules | July 13, 2021 | Volume: 11 | Issue: 7 | Pages: 1020

10.3390/biom11071020 | PMID 34356644 Get It

Two adenovirus-based vaccines, ChAdOx1 nCoV-19 and Ad26.COV2.S, and two mRNA-based vaccines, BNT162b2 and mRNA.1273, have been approved by the European Medicines Agency (EMA), and are invaluable in preventing and reducing the incidence of coronavirus disease-2019 (COVID-19). Recent reports have pointed to thrombosis with associated thrombocytopenia as an adverse effect occurring at a low frequency in some individuals after vaccination. The causes of such events may be related to SARS-CoV-2 spike protein interactions with different C-type lectin receptors, heparan sulfate proteoglycans (HSPGs) and the CD147 receptor, or to different soluble splice variants of the spike protein, adenovirus vector interactions with the CD46 receptor or platelet factor 4 antibodies. Similar findings have been reported for several viral diseases after vaccine administration. In addition, immunological mechanisms elicited by viral vectors related to cellular delivery could play a relevant role in individuals with certain genetic backgrounds. Although rare, the potential COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) requires immediate validation, especially in risk groups, such as the elderly, chronic smokers, and individuals with pre-existing incidences of thrombocytopenia; and if necessary, a reformulation of existing vaccines.
Feasibility of an Innovative Absorbable Ventilation Tube Designed to Provide Intermediate‐Term Middle Ear Ventilation
Skovlund, Sandra M., Cofer, Shelagh A. , Weinreich, Heather M. , Cofer, Shelagh

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 13, 2021 | Volume: 166 | Issue: 3 | Pages: 598-600

10.1177/01945998211026543 | PMID 34253079 Get It

Myringotomy with ventilation tube placement is a common surgical procedure performed in children and adults to remove fluid buildup behind the tympanic membrane. However, retention of tubes beyond achievement of therapeutic response increases risk for complications and additional intervention. This small feasibility study was conducted to demonstrate proof of concept of a novel bioabsorbable ventilation tube that provides the necessary duration of ventilation with absorption shortly thereafter. Tubes were placed in 15 ears of 14 patients meeting indications for short or intermediate duration of middle ear ventilation. Two independent examiners documented tube patency and tube absorption status at 3, 6, and 12 weeks or until absorption was complete. Results indicate that average ventilation time was 12 weeks (range, 3 weeks to 18 months). There was no observation of blockage. These findings support the feasibility of a novel bioabsorbable ventilation tube.
Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma
Paulino, Arnold C. , Ludmir, Ethan B. , Grosshans, David R. , Su, Jack , McGovern, Susan L. , Okcu, M. Fatih , McAleer, Mary Frances , Baxter, Patricia , Mahajan, Anita , Chintagumpala, Murali , Paulino, Arnold C , Ludmir, Ethan B

Mayo Clinic

Cancer | July 13, 2021 | Volume: 127 | Issue: 20 | Pages: 3865-3871

10.1002/cncr.33783 | PMID 34254296 Get It

BACKGROUNDBoth intensity‐modulated radiotherapy (RT) and passively scattered proton therapy have a risk of secondary malignant neoplasm (SMN) in children. To determine the influence of RT modality on the incidence of SMN after craniospinal irradiation (CSI), the authors compared the incidence of SMN in children who had medulloblastoma treated with either photon CSI plus an intensity‐modulated RT boost (group I) or passively scattered proton CSI plus a boost (group II).METHODSFrom 1996 to 2014, 115 children with medulloblastoma (group I, n = 63; group II, n = 52) received CSI followed by a boost to the tumor bed. Most patients had standard‐risk disease (63.5%). The median follow‐up was 12.8 years for group I and 8.7 years for group II.RESULTSThe 5‐year and 10‐year overall survival (OS) rates were 88.8% and 85.1%, respectively, for standard‐risk patients and 63.1% and 57.3%, respectively, for high‐risk patients, with no OS difference by RT modality (P = .81). Six SMNs were identified (4 in group I, 2 in group II). The 5‐year and 10‐year SMN incidence rates were 1.0% and 6.9%, respectively (0.0% and 8.0%, respectively, in group I; 2.2% and 4.9%, respectively, in group II; P = .74). Two SMNs occurred in the clinical target volume in the brain, 2 occurred in the exit dose region from the photon spinal field, 1 occurred in the entrance path of a proton beam, and 1 occurred outside the radiation field. There were no reported cases of secondary leukemia.CONCLUSIONSThis analysis demonstrates no difference in OS or SMN incidence between patients in groups I and II 10 years after RT.LAY SUMMARY One hundred fifteen children with medulloblastoma received radiotherapy (RT) with either photon craniospinal irradiation (CSI) and an intensity‐modulated RT boost (group I; n = 63) or passively scattered proton CSI and a boost (group II;, n = 52). The majority of children had standard‐risk disease (63.5%). The 5‐year and 10‐year overall survival rates were 88.8% and 85.1% for standard‐risk patients, respectively, and 63.1% and 57.3% for high‐risk patients, respectively, with no difference in overall survival by RT group (P = .81). The 5‐year and 10‐year second malignant neoplasm incidence rates were 1.0% and 6.9%, respectively, with no difference in second malignant neoplasm incidence according to RT group (P = .74).
The new Roche Elecsys TSH assay conforms with current IFCC C-STFT standards
Kratzsch, Jüergen, Baumann, N, Ceriotti, Ferruccio , Lu, Zhong X. , Herwaarden, Antonius E. van , Lehmann, H. , Kasapic, Dusanka , Giovanella, Luca , Baumann, Nikola A, Giovanella, Luca , Schott, Matthias , Vieira, José Gilberto H. , Lehmann, Holger

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | July 12, 2021 | Volume: 59 | Issue: 12 | Pages: e445-e448

10.1515/cclm-2021-0352 | PMID 34252995 Get It

Autophagy and Tau Protein
Hamano, Tadanori , Enomoto, Soichi, Shirafuji, Norimichi, Ikawa, Masamichi , Yamamura, Osamu , Yen, Shu-Hui, Nakamoto, Yasunari

Mayo Clinic

International Journal of Molecular Sciences | July 12, 2021 | Volume: 22 | Issue: 14 | Pages: 7475

10.3390/ijms22147475 | PMID 34299093 Get It

Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzheimer’s disease (AD). In swollen axons, many autophagic vacuoles are observed around SP in the AD brain. This suggests that autophagy function is disturbed in AD. We used a neuronal cellular model of tauopathy (M1C cells), which harbors wild type tau (4R0N), to assess the effects of the lysosomotrophic agent NH4Cl, and autophagy inhibitors chloroquine and 3 methyladenine (3MA). It was found that chloroquine, NH4Cl and 3MA markedly increased tau accumulation. Thus, autophagy lysosomal system disturbances disturbed the degradation mechanisms of tau protein. Other studies also revealed that tau protein, including aggregated tau, is degraded via the autophagy lysosome system. Phosphorylated and C terminal truncated tau were also reported to disturb autophagy function. As a therapeutic strategy, autophagy upregulation was suggested. Thus far, as autophagy modulators, rapamycin, mTOCR1 inhibitor and its analogues, lithium, metformin, clonidine, curcumin, nicotinamide, bexaroten, and torehalose have been proposed. As a therapeutic strategy, autophagic modulation may be the next target of AD therapeutics.
A New Look at an Old Problem: Improving Diversity, Equity, and Inclusion in Scientific Research
Henry, Brandon V., Faber, Lydia , Freischlag, Julie A. , Edwards, Michael A. , Henry, Brandon V., Chen, Herbert

Mayo Clinic

The American Surgeon™ | July 12, 2021 | Volume: 87 | Issue: 11 | Pages: 1722-1726

10.1177/00031348211029853 | PMID 34253091 Get It

Uncertainty in tissue equivalent proportional counter assessments of microdosimetry and RBE estimates in carbon radiotherapy
Hartzell, Shannon , Guan, Fada , Taylor, Paige A. , Peterson, Christine B. , Taddei, P , Kry, Stephen F. , Taylor, Paige , Peterson, Christine , Taddei, Phillip , Kry, Stephen

Mayo Clinic

Physics in Medicine & Biology | July 12, 2021 | Volume: 66 | Issue: 15 | Pages: 155018

10.1088/1361-6560/ac1366 | PMID 34252894 Get It

Abstract Microdosimetry is an important tool for assessing energy deposition distributions from ionizing radiation at cellular and cellular nucleus scales. It has served as an input parameter for multiple common mathematical models, including evaluation of relative biological effectiveness (RBE) of carbon ion therapy. The most common detector used for microdosimetry is the tissue-equivalent proportional counter (TEPC). Although it is widely applied, TEPC has various inherent uncertainties. Therefore, this work quantified the magnitude of TEPC measurement uncertainties and their impact on RBE estimates for therapeutic carbon beams. Microdosimetric spectra and frequency-, dose-, and saturation-corrected dose-mean lineal energy (****) were calculated using the Monte Carlo toolkit Geant4 for five monoenergetic and three spread-out Bragg peak carbon beams in water at every millimeter along the central beam axis. We simulated the following influences on these spectra from eight sources of uncertainty: wall effects, pulse pile-up, electronics, gas pressure, W-value, gain instability, low energy cut-off, and counting statistics. Statistic uncertainty was quantified as the standard deviation of perturbed values for each source. Bias was quantified as the difference between default lineal energy values and the mean of perturbed values for each systematic source. Uncertainties were propagated to RBE using the modified microdosimetric kinetic model (MKM). Variance introduced by statistic sources in y ¯ F and y ¯ D averaged 3.8% and 3.4%, respectively, and 1.5% in y * across beam depths and energies. Bias averaged 6.2% and 7.3% in y ¯ F and y ¯ D , and 4.8% in y * . These uncertainties corresponded to 1.2 ± 0.9% on average in RBE MKM . The largest contributors to variance and bias were pulse pile-up and wall effects. This study established an error budget for microdosimetric carbon measurements by quantifying uncertainty inherent to TEPC measurements. It is necessary to understand how robust the measurement of RBE model input parameters are against this uncertainty in order to verify clinical model implementation.
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Walker, Alison R. , Marcucci, Guido , Yin, Jun , Blum, William , Kohlschmidt, Jessica, Mrózek, Krzysztof , Carroll, Andrew J. , Eisfeld, Ann-Kathrin, Kolitz, Jonathan E. , Thakuri, Mohan C., Sutamtewagul, Grerk , Vij, Ravi , Byrd, John C. , Bloomfield, Clara D. , Stone, Richard M. , Byrd, John C. , Jacobson, Sawyer , Sutamtewagul, Grerk , Larson, Richard A , Stock, Wendy , Eisfeld, Ann‐Kathrin , Wang, Eunice S. , Stuart, Robert K. , Larson, Richard A. , Byrd, John C

Mayo Clinic

Blood Advances | July 12, 2021 | Volume: 5 | Issue: 13 | Pages: 2775-2787

10.1182/bloodadvances.2021004233 | PMID 34251414 Get It

Abstract Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. In this phase 3 trial, untreated older AML patients were randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2 per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days 4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P = .13), with no differences in disease-free (DFS; P = .26) or event-free survival (P = .80). Subgroup analyses showed patients age <70 years in arm A had improved OS by 1 month vs those in arm B (P = .04), and patients with secondary AML in arm A had better DFS vs those in arm B (P = .04). We conclude that addition of G3139 to chemotherapy failed to improve outcomes of older AML patients. However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. This trial was registered at www.clinicaltrials.gov as #NCT00085124.